{"created":"2023-06-19T10:43:25.925810+00:00","id":3658,"links":{},"metadata":{"_buckets":{"deposit":"235a030e-6e0f-4236-b2c4-f3d2da9e26ae"},"_deposit":{"created_by":11,"id":"3658","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"3658"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00003658","sets":["30:261:262","30:422:423"]},"author_link":["494","454","456","2998"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"11","bibliographicPageStart":"6","bibliographicVolumeNumber":"12","bibliographic_titles":[{},{"bibliographic_title":"Journal of Contemporary Brachytherapy","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"岡本, 圭生"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"奥山, 佳ほり"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"河野, 直明"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"津川, 拓也"}],"nameIdentifiers":[{}]}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose:\nTo monitor the outcomes for intermediate-risk prostate cancer patients treated with biologically effective dose (BED) ≥ 200 Gy radiotherapy using low-dose-rate (LDR) brachytherapy. ","subitem_description_type":"Abstract"},{"subitem_description":"Material and methods:\nBetween 2005 and 2016, a total of 397 patients with intermediate-risk prostate cancer were treated by LDR-based radiotherapy with a BED ≥ 200 Gy. Treatments consisted of LDR brachytherapy alone (177 cases) or LDR and external beam radiotherapy (EBRT) (220 cases). Short-term androgen deprivation therapy (ADT) was used in 186 patients (46.9%). The median follow-up period was 72 months (range 29-165 months). Dosimetric parameters and BED were studied in each case. The numbers of intermediate-risk features were: 163 patients with 1 intermediate-risk feature (41%), 169 patients with 2 intermediate-risk features (43%), and 65 patients with 3 intermediate-risk features (16%). A total of 145 cases were diagnosed as having primary Gleason pattern 4: Gleason score 4 + 3 (36.5%). ","subitem_description_type":"Abstract"},{"subitem_description":"Results:\nThree patients developed biochemical failure, thus providing a 7-year actual biochemical failure-free survival (BFFS) rate of 99.1%. Biochemical failure was observed exclusively in cases with distant metastasis: two cases with lymph node metastasis and one case with bone metastasis, thus yielding a 7-year freedom from clinical failure (FFCF) rate of 99.1%. We observed eight deaths, but there was no death from prostate cancer, thus yielding a 7-year cause-specific survival (CSS) rate of 100%, and an overall survival (OS) rate of 98.4%. ","subitem_description_type":"Abstract"},{"subitem_description":"Conclusions:\nThis study highlights excellent outcomes for intermediate-risk prostate cancer patients, including unfavorable intermediate-risk cases, treated with BED ≥ 200 Gy radiotherapy using LDR brachytherapy. LDR alone with a BED of 200 Gy may be an optimal treatment for both favorable and unfavorable intermediate-risk prostate cancer patients, although a longer follow-up is mandatory to confirm the present findings. ","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Termedia Pub. House"}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"32190064","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.5114/jcb.2020.92405"}],"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.5114/jcb.2020.92405","subitem_relation_type_select":"DOI"}}]},"item_4_relation_13":{"attribute_name":"PMCID","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"PMC7073334"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7073334/","subitem_relation_type_select":"URI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2020 Termedia. "}]},"item_4_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2081-2841","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"OKAMOTO, Keisei"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"OKUYAMA, Kahori"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KOHNO, Naoaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TSUGAWA, Takuya"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-08-17"}],"displaytype":"detail","filename":"jcb.2020.92405.pdf","filesize":[{"value":"240.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"jcb.2020.92405","url":"https://shiga-med.repo.nii.ac.jp/record/3658/files/jcb.2020.92405.pdf"},"version_id":"0dba2914-4fee-4777-8466-ea85d0211f50"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"brachytherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"intermediate risk","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"low-dose-rate","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"prostate cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer."}]},"item_type_id":"4","owner":"11","path":["262","423"],"pubdate":{"attribute_name":"公開日","attribute_value":"2020-08-17"},"publish_date":"2020-08-17","publish_status":"0","recid":"3658","relation_version_is_last":true,"title":["Clinical outcomes of low-dose-rate brachytherapy based radiotherapy for intermediate risk prostate cancer."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T11:20:23.987407+00:00"}